VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 410 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2013. The put-call ratio across all filers is 0.62 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2016 | $6,229,000 | -78.9% | 236,839 | -18.0% | 0.01% | -78.8% |
| Q4 2015 | $29,575,000 | +25.9% | 289,002 | +119.4% | 0.05% | +18.2% |
| Q3 2015 | $23,492,000 | -61.8% | 131,695 | -52.4% | 0.04% | -55.6% |
| Q2 2015 | $61,441,000 | -17.5% | 276,552 | -26.2% | 0.10% | -27.7% |
| Q1 2015 | $74,453,000 | -24.4% | 374,827 | -45.6% | 0.14% | -20.3% |
| Q4 2014 | $98,487,000 | -16.6% | 688,590 | -23.4% | 0.17% | -18.1% |
| Q3 2014 | $118,026,000 | +14.3% | 899,418 | +2.2% | 0.21% | +16.7% |
| Q2 2014 | $103,297,000 | +111.6% | 880,212 | +137.8% | 0.18% | +109.3% |
| Q1 2014 | $48,811,000 | -44.9% | 370,194 | -43.7% | 0.09% | -47.2% |
| Q4 2013 | $88,646,000 | +11.8% | 657,540 | -13.5% | 0.16% | +17.3% |
| Q3 2013 | $79,308,000 | +3.8% | 760,295 | -14.3% | 0.14% | -0.7% |
| Q2 2013 | $76,382,000 | – | 887,620 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
| Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
| LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
| Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
| FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
| Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
| Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
| Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
| Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
| ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |